Abstract:ObjectiveTo evaluate the shortterm efficacy, safety and impact on the quality of life of anlotinib in thirdline and above treatment for advanced nonsmall cell lung cancer (NSCLC) patients. MethodsAll the patients received alotinib 12 mg/d. One cycle was defined as 2 weeks ontreatment followed by 1 week offtreatment until disease progression or treatment intolerance. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to assess tumor responses. Common Terminology Criteria for Adverse Events (CTCAE) 4.02 was used to assess the adverse events. The European Organization for Research on Treatment of Cancer (EORTC) QLQC30 and QLQLC13 were used to assess quality of life. ResultsAmong 27 patients in study, no complete response (CR) was found, 2 patients (7.4%) achieved partial response (PR), 16 patients (59.3%) achieved stable disease (SD), 9 patients (33.3%) achieved progressive disease (PD), objective response rate (ORR) was 7.4%, and disease control rate (DCR) was 66.7%. The scores of physical functioning (76.00±10.55 vs. 64.44±11.59), emotional functioning (81.67±8.71 vs. 76.11±6.71) and global health status (48.87±7.97 vs. 40.56±12.49) of the QLQC30 scale after treatment were higher than those before treatment, with statistically significant differences (t=-4.516, P<0.001; t=-2.646, P=0.019; t=-3.872, P=0.002). Fatigue (50.37±8.95 vs. 40.74±13.86), nausea and vomiting (26.54±16.18 vs. 14.20±11.97), loss of appetite ［M(QR): 33.33(33.33) vs. 33(33.33)］ were better than before (t=-2.476, P=0.027; t=-5.036, P＜0.001; Z=-2.923, P=0.003); pain (28.88±14.23 vs. 33.33±13.60) and dyspnea ［33.33(33.33) vs. 33.33(66.67)］ scores were lower than before (t=3.674, P=0.003; Z=-3.266, P=0.001). The scores of cough (24.44±19.12 vs. 45.24±20.34), shortness of breath ［11.11(22.22) vs. 33.33(22.22)］ and chest pain ［0.00(33.33) vs. 33.33(33.33)］ in the QLQLC13 scale after treatment were lower than those before treatment, with statistically significant differences (t=4.000, P=0.001; Z=-4.125, P＜0.001; Z=-1.890, P=0.034); the scores of sore mouth or tongue ［0.00(33.33) vs. 0.00(0.00)］ and hands and feet tingling ［33.33(33.33) vs. 0.00(0.00)］ were higher than before (Z=-2.000, P=0.046; Z=-2.264, P=0.024). Common adverse reactions included hypertension, fatigue, elevated thyroid stimulating hormone, proteinuria, handfoot syndrome, oral mucositis, hemoptysis, etc, mainly grade 12, and they were all improved after the treatments. ConclusionAnlotinib as a thirdline and further therapy is positive effected and well tolerated. It can alleviate the clinical symptoms and significantly improve the quality of life of NSCLC patients.

Key words:Carcinoma, non-small-cell lung,Receptors, vascular endothelial growth factor,Quality of life,Anlotinib